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Impact of V-ets Erythroblastosis Virus E26 Oncogene
Homolog 1 Gene Polymorphisms Upon Susceptibility
to Autoimmune Diseases
A Meta-Analysis
Ye Zhou, PhD, Miao Liu, PhD, Jun Li, MD, Fiza Hashmi, MS, Zhi Mao, MD, Ning Zhang, MD,
Liang Zhou, PhD, Weiran Lv, MD, Jingwei Zheng, MD, Xiaoli Nie, MD, and Changzheng Li, MD, PhD
Abstract: V-ets erythroblastosis virus E26 oncogene homolog 1
(ETS1) is recognized as a gene of risk to autoimmune diseases
(ADs). Two single nucleotide polymorphisms (SNPs) in ETS1
(rs1128334 G>A and rs10893872 T>C) were considered associated
with ADs risk. However, the results remain conflicting.
Weperformed ameta-analysis to evaluatemore precise estimations of
any relationship. We searched PubMed, OvidSP, and Chinese National
Knowledge Infrastructure databases (papers published prior to September
12, 2014) and extracted data from eligible studies. Meta-analysis was
performed using the STATA12.0 software. Random effectmodel or fixed
effect model were chosen according to the study heterogeneities.
A total of 11 studies including 7359 cases (9660 controls) for
rs1128334 and 8 studies including 5419 cases (7122 controls) for
rs10893872 were involved in this meta-analysis. Overall, our results
showed that there were significant associations for rs1128334 with AD
risk in 5 genetic models, both in pooled analysis and in systemic lupus
erythematous (SLE) subgroup, and in 3 genetic models of the uveitis
subgroup. Although for rs10893872, the results showed that there were
significant associations in allelemodel both in pooled analysis and in SLE
subgroup.
As a conclusion, this meta-analysis demonstrated that these 2 SNPs
(rs1128334 and rs10893872) in ETS1 were associated with ADs risk.
(Medicine 94(22):e923)
Abbreviations: AD = autoimmune disease, ETS1 = V-ets
erythroblastosis virus E26 oncogene homolog 1, HWE = Hardy–
Weinberg equilibrium, SNP = single nucleotide polymorphism,
TH17 = T helper 17.
INTRODUCTION
A utoimmune diseases (ADs) are initiated by abnormalimmune response to self-antigen and can result in
immune-mediated tissue destruction and chronic disabilities.1,2
There are >100 ADs and syndromes, which cause a heavy
economic burden in the world, about >$100 billion annually.3
More evidence has emerged and showed that genetic back-
ground played an important role in the pathogenesis of ADs.4,5
The sustained pathology of ADs could be widely regulated
by a variety of molecules; V-ets erythroblastosis virus E26
oncogene homolog 1 (ETS1) was included as 1 possibility.
ETS1 was the first member of ETS oncogene family, and could
regulate tumor development and progression.6 Evidence shows
that ETS1 could engage into immunology by downregulating the
differentiation of not only B cell but also T helper 17 (TH17)
cell.7,8 Recent articles show that ETS1was associated with some
types of ADs.9–11 ETS1 can be recognized as a risk gene of ADs.
Single nucleotide polymorphisms (SNPs) or mutations in
the genetic sequence may alter the expression of the gene.12–16
Some researchers paid attention to the relationship between AD
risk and 2 polymorphisms of ETS1, namely ETS1 rs1128334
G>A and ETS1 rs10893872 T>C.10,17–22 However, the results
remain conflicting.Therefore,we conducted thismeta-analysis to
make a clarified association between these 2 SNPs and AD risk.
METHODS
Publication Search
A systematic search was performed in PubMed, OvidSP,
and Chinese National Knowledge Infrastructure databases cov-
ering all the papers published before September 12, 2014. The
search strategy was as follows: (autoimmune OR autoimmune
disease OR autoimmunity) AND (polymorphism OR poly-
morphisms OR variation OR variations OR mutation OR
mutations OR variant OR variants) AND (ETS1 OR ETS-1
OR rs1128334 OR rs10893872). The references in these studies
were also read to find additional publications on this topic.
Articles included met the following criteria: case–control
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study; evaluation of ETS1 polymorphisms (rs1128334 or
rs10893872) and risk of ADs; available and usable data of
genotype frequency.
Data Extraction
Two authors (Y.Z. and M.L.) independently extracted the
data from eligible studies. Data extracted by Y.Z. and M.L. were
checked by the third author J.L. The remaining disagreements
were discussed and judged by these 3 authors. The following
information was extracted: the first author, publication year,
diseases, country, genotyping methods, number of cases and
controls, the gender distribution of cases and controls, number
of genotypes and alleles, Hardy–Weinberg equilibrium (HWE)
in control subjects, and the frequency of major allele in controls.
Study qualities were judged according to the criteria modified
from previous publications23–26 (supplementary Table S1,
http://links.lww.com/MD/A289).
Statistical Analysis
Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated as a measure of the association between these
2 SNPs (rs1128334 and rs10893872) and AD risk. Allele model
and other different type of genetic models (heterozygote, homo-
zygote, dominant, and recessive) were used. In addition to
comparing among all subjects, the stratified comparisons were
also used according to different ethnicities and different dis-
eases. The between-study heterogeneity was measured by
Cochran (Q) and Higgins (I2) tests. If the heterogeneity was
considered significant (P< 0.05), the random effects model was
used to estimate the pooled OR. Otherwise, the fixed effects
model was conducted. Also, logistic meta-regression analysis
was carried out, if there was obvious significant heterogeneity,
to explore potential sources of heterogeneity. The examined
characteristics include publication years, countries, genotyping
methods, number of alleles and genotypes, number of female
and male patients, and the frequency of major allele in SNP in
controls. The HWE was examined using x2 test with signifi-
cance set at P< 0.05. Sensitivity analysis was performed to
evaluate the effect of each study on the combined ORs by
deleting each study in each turn. Potential publication bias was
determined by using Funnel plots and Egger test. An asym-
metric plot and the P value <0.05 was recognized as signifi-
cance. All statistical analyses were performed by STATA 12.0
software (STATA Corp, College Station, TX). As a meta-
analysis study, ethical approval of this study is not required.
This study was reported following the PRISMA guidelines.
RESULTS
Study Characteristics
A total of 432 articles matched the search strategy and an
additional article17 was found by scanning the references of
original papers. After step-by-step screening of the titles,
abstracts and full-texts of the articles, as shown in Fig. 1, there
were 7 articles appropriate for this meta-analysis, which con-
tained 11 studies for rs1128334, with 7359 cases (9660 con-
trols), and 8 studies for rs10893872, with 5419 cases (7122
controls).
Within all 7 articles, 2 kinds of genotyping methods were
used. Only the Asian race was included. The patients in these
studies with Behcet Disease (BD), Vogt–Koyanagi–Harada
syndrome (VKH), Fuchs uveitis syndrome (FUS), and pediatric
uveitis (PU) were all suffering uveitis, which is a common
syndrome of ADs. So, these studies were included into uveitis
subgroup. There was 1 study not in HWE in control group,19 and
there was not enough data in another article.10 The detail
characteristics are shown in Table 1.
Association Between ETS1 rs1128334 G>A
Polymorphism and ADs Risk
First, the association between rs1128334 G>A poly-
morphism and the risk of AD was analyzed. Significantly
increased risks of A allele, GA genotype, AA genotype and
GAþAA genotype with ADs were observed in each genetic
model in the pooled analyses, respectively (allele model, A vs
G, OR 1.28, 95%CI 1.16–1.42, P¼ 0.000; heterozygote model,
GA vs GG, OR 1.18, 95% CI 1.02–1.38, P¼ 0.030; homo-
zygote model, AA vs GG, OR 1.72, 95% CI 1.24–2.40,
P¼ 0.001; dominant model, GAþAA vs GG, OR 1.28, 95%
CI 1.07–1.53, P¼ 0.006; recessive model, OR 1.57, 95% CI
1.19–2.06, P¼ 0.001) (Table 2 and Fig. 2A–E).
Next, we analyzed the studies by subgroup analysis
according to diseases. In systemic lupus erythematosus
(SLE) subgroup, there were increased disease risks in A allele,
GA genotype, AA genotype and GAþAA genotype in each
genetic model, respectively (allele model, A vs G, OR 1.44,
95% CI 1.24–1.68, P¼ 0.000; heterozygote model, GA vs GG,
OR 1.61, 95% CI 1.29–2.01, P¼ 0.000; homozygote model,
FIGURE 1. Flowchart for identification of studies included in the
meta-analysis. In 433 articles, 33 were found not related to ADs
and 90 were found not related to ETS1 by scanning the titles.
After that, 178 articles were recognized as reviews, 85 were found
not related to human patients, and 4 articles were repeated papers
by reviewing the abstracts. The full-text of the left 43 articles were
carefully reviewed, in which 1 article was found not include usable
data and 35 articles were found not about rs1128334 or
rs10893872. At last, 7 articles remained for this meta-analysis,
which included 11 case–control studies for rs1128334 and 8
studies for rs10893872. AD¼ autoimmune disease; ETS1¼
V-ets erythroblastosis virus E26 oncogene homolog 1.
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AA vs GG, OR 4.01, 95% CI 2.86–5.62, P¼ 0.000; dominant
model, GAþAA vs GG, OR 1.95, 95% CI 1.58–2.40,
P¼ 0.000; recessive model, OR 3.12, 95% CI 2.28–4.27,
P¼ 0.000) (Table 2 and supplementary Figure S1A–E,
http://links.lww.com/MD/A289). In the uveitis subgroup, there
were increased risks in A allele and AA genotype in allele
model (A vs G, OR 1.11, 95% CI 1.03–1.20, P¼ 0.007),
homozygote model (AA vs GG, OR 1.29, 95% CI 1.09–1.52,
TABLE 2. Stratified Analysis of Association Between ADs Risk and rs1128334
Effects size Heterogeneity
Gene Model Stratify Study, n OR (95% CI) P I2, % P Effect Model
Allele model (A vs G) Total 11 1.28 (1.16–1.42) <0.001 79.5 0.000 Random
Diseases
SLE 6 1.44 (1.24–1.68) <0.001 81.5 0.000 Random
Uveitis 4 1.11 (1.03–1.20) 0.007 0.0 0.444 Fixed
Heterozygote model
(GA vs GG)
Total 7 1.18 (1.02–1.38) 0.030 65.8 0.008 Random
Diseases
SLE 2 1.61 (1.29–2.01) <0.001 0.0 0.765 Fixed
Uveitis 4 1.05 (0.94–1.17) 0.411 34.7 0.204 Fixed
Homozygote model
(AA vs GG)
Total 7 1.72 (1.24–2.40) 0.001 84.1 0.000 Random
Diseases
SLE 2 4.01 (2.86–5.62) <0.001 0.0 0.839 Fixed
Uveitis 4 1.29 (1.09–1.52) 0.003 0.0 0.564 Fixed
Dominant model
(GAþAA vs GG)
Total 7 1.28 (1.07–1.53) 0.006 77.8 0.000 Random
Diseases
SLE 2 1.95 (1.58–2.40) <0.001 0.0 0.797 Fixed
Uveitis 4 1.10 (0.99–1.22) 0.084 21.2 0.283 Fixed
Recessive model
(AA vs GGþGA)
Total 7 1.57 (1.19–2.06) 0.001 79.6 0.000 Random
Diseases
SLE 2 3.12 (2.28–4.27) <0.001 0.0 0.925 Fixed
Uveitis 4 1.25 (1.08–1.46) 0.004 0.0 0.495 Fixed
AD¼ autoimmune disease; CI¼ confidence interval; OR¼ odds ratio.
FIGURE 2. Forest plots of overall analysis of ADs risk associated with ETS1. (A–E) Forest plots of overall analysis of ADs risk associated with
rs1128334. (A) Allele model, A vs G, random model; (B) heterozygote model, GA vs GG, random model; (C) homozygote model, AA vs
GG, random model; (D) dominant model, GAþAA vs GG, randommodel; (E) recessive model, AA vs GGþGA, random model. (F) Forest
plots of overall analysis of ADs risk associated with rs10893872. Allele model, C vs T, random model. AD¼ autoimmune disease;
CI¼ confidence interval; ETS1¼V-ets erythroblastosis virus E26 oncogene homolog 1; OR¼odds ratio.
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P¼ 0.003), and recessivemodel (AA vsGGþGA,OR 1.25, 95%
CI 1.08–1.46, P¼ 0.004), respectively (Table 2 and supple-
mentary Figure S1F–H, http://links.lww.com/MD/A289).
Association Between ETS1 rs10893872 T>C
Polymorphism and AD Risk
For the association between rs10893872 T>C polymorph-
ism and AD risk, there was significantly increased risk of C
allele in overall comparison in allele model (C vs T, OR 1.17,
95% CI 1.08–1.28, P¼ 0.000) (Table 3 and Fig. 2F). Based on
the data limitation, the stratified analysis could only be con-
ducted in the allele model, and the increased risk was found in
SLE subgroup (allele model, C vs T, OR 1.22, 95% CI 1.14–
1.30, P¼ 0.000) (Table 3 and supplementary Figure S1I, http://
links.lww.com/MD/A289).
Evaluation of Heterogeneity
The heterogeneities among studies were obvious in the
overall comparisons (rs1128334, I2¼ 79.5%, i2¼ 0.022,
P¼ 0.000; rs10893872, I2¼ 65.1%, i2¼ 0.010, P¼ 0.005).
The meta- regression analysis was conducted to further explore
sources of heterogeneity. Several factors were tested as potential
sources of heterogeneity, including publication years, countries,
genotypingmethods, number of genotypes and alleles, number of
female and male patients, and the frequencies of major allele for
each SNP in controls. For rs1128334, the genotyping methods
(adjusted R2¼ 40.83%) and the frequency of G allele in control
(adjustedR2¼ 73.00%) could partially explain the heterogeneity,
whereas for rs10893872, the heterogeneity couldnot be explained
by any of the potential sources above.
Sensitivity and Publication Bias Analysis
We performed the sensitivity analysis to test the influence of
a single study on the overall meta-analysis by deleting each study
once a time. As a result, the pooled estimate did not show
significant difference (data not shown), which indicated that the
results were statistically reliable. No evidence of publication bias
was found in current meta-analysis, identified by the Begg test
(P¼ 0.640 for rs1128334, P¼ 0.711 for rs10893872) and Egger
test (P¼ 0.546 for rs1128334,P¼ 0.569 for rs10893872) (Fig. 3).
DISCUSSION
ETS1 is a member of the ETS transcription factor families.
It is expressed by a variety of cell types and regulates several
functions in some cell signaling pathways.27 The differentiation
of both B cell and TH17 cell could be inhibited by ETS1.
7,8
Animal experiments showed that lupus-like disease could easily
be developed in ETS1-deficient mice.28 Then, ETS1 was found
to be associated with SLE based on human data.9,10 As the
clinical and immunological overlap of SLE and other ADs,29
other researchers found the association of ETS1 and ankylosing
spondylitis (AS).20
Some articles reported the relationship between 2 variants
(rs1128334 and rs10893872) in ETS1 and susceptibility to ADs,
such as SLE, BD, and VKH.10,17 However, the results remain
conflicting. Maybe due to different disease types included in
ADs, some studies showed that these 2 SNP in ETS1 were
associated with susceptibility to ADs, whereas other studies did
not. Therefore, we conducted this meta-analysis, including
pooled analysis and subgroup analysis based on different dis-
ease types, in order to better understand whether these 2 SNPs
contribute to the susceptibility to ADs.
In this meta-analysis, we screened 7 manuscripts and
pooled the corresponding data including 7359 cases (9660
controls) for rs1128334 and 5419 cases (7122 controls) for
rs10893872. We found that all these 2 SNPs were related to AD
risk with distinct degree, respectively.
For rs1128334, A allele, GA genotype, AA genotype, and
GAþAA genotype were all found correlated with increased risk
of ADs in each genetic model, both in pooled analyses and in
SLE subgroup. Moreover, the increased disease risk of A allele
and AA genotype were also found in the allele model, homo-
zygote model and recessive model in Uveitis subgroup. For
rs10893872, C allele was found to be associated with increased
disease risk in allele model, both in pooled analyses and in SLE
subgroup. However, there was not any significant association in
other genetic models.
There are some limitations in our studies. First, although
there were 7 articles included, the studies for some stratified
analyses were limited. For example, there were only 2 studies
for SLE subgroup in analyses for rs1128334, except in the allele
model, whereas there was not enough data to do the stratified
analysis for rs10893872 in 4 genetic models, except in the allele
model. Also, there was only the data about Asian populations.
Further studies based on other ethnic populations will be
needed. Second, there were obvious heterogeneities between
different groups for some genetic models. Although the meta-
regression and sensitivity analyses were conducted, and we
found that in rs1128334 the variation of G allele frequency in
controls and different genotyping methods could partly explain
TABLE 3. Stratified Analysis of Association Between ADs Risk and rs10893872
Effects Size Heterogeneity
Gene Model Study, n OR (95% CI) P I2 (%) P Effect Model
Allele model (C vs T) 8 1.17 (1.08–1.28) <0.001 65.1 0.005 Random
SLE 4 1.22 (1.14–1.30) <0.001 0.0 0.635 Fixed
Uveitis 4 1.12 (0.95–1.33) 0.179 79.4 0.002 Random
Heterozygote model (TC vs TT) 4 0.97 (0.84–1.12) 0.664 0.0 0.651 Fixed
Homozygote model (CC vs TT) 4 1.21 (0.89–1.64) 0.227 72.8 0.012 Random
Dominant model (TCþCC vs TT) 4 1.05 (0.91–1.20) 0.513 6.0 0.363 Fixed
Recessive model (CC vs TTþTC) 4 1.23 (0.92–1.66) 0.164 84.6 0.000 Random
AD¼ autoimmune disease; CI¼ confidence interval; OR¼ odds ratio; SLE¼ systemic lupus erythematous.
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some heterogeneity, the results still needed to be treated with
caution. Third, only 2 SNPs in ETS1were included in this study.
Some other SNPs in ETS1 also could contribute to susceptibility
to ADs. Not only should the effect of these SNPs, but the
interaction or network among these related genes also be studied
in the future. Furthermore, studies investigating the gene-
environment interactions will also help to make clear of the
role of these SNPs in the pathology of ADs. Finally, since ADs
consist of diverse diseases, the relationship of these SNPs with
other type of ADs, such as rheumatoid arthritis, inflammatory
bowel disease and seronegative spondyloarthropathies, should
be investigated in the future.
As a conclusion, our study demonstrated that these 2 SNPs
(rs1128334 and rs10893872) in ETS1 confer risk of ADs.
Considering the limitation of our study, large sample studies
including different ethnic populations and other type of ADs
will be needed to confirm the results of this analysis.
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